Telix was created to deliver on the promise of nuclear medicine.
Nuclear medicine has historically suffered from a lack of commercial critical mass and commitment to late-stage product development. Molecularly-targeted radiation (MTR) potentially offers better-informed treatment decisions and truly personalised therapy. Our product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.
We are an experienced team of drug developers, clinicians and executives, with a passion for radiation biology and oncology. Telix’s pipeline currently focuses on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio.
In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.
Through collaboration, we multiply our contribution to the delivery of our goals and to improving the lives of those living with cancer.
We implement new ideas & technologies to meet our goals and the unmet medical needs of people living with cancer.
We are trustworthy and reliable, we practice and encourage open communication, we are responsible for our actions.
We are passionate about delivering on our goals and improving the lives of people living with cancer.
We respect our colleagues, our collaborators, our mentors, and the collective contribution of experts in our field.